NO314581B1 - Opplösning av aminer - Google Patents

Opplösning av aminer Download PDF

Info

Publication number: NO314581B1
Authority: NO; Norway
Prior art keywords: ditoluyl; acid; mixture; tartaric acid; methyl
Prior art date: 1997-07-10

Application number

NO20000089A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000089D0 (no

NO20000089L (no

Inventor

Antoni Torrens-Jover

Jordi Frigola-Constansa

Original Assignee

Esteve Labor Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-10

Filing date

2000-01-07

Publication date

2003-04-14

2000-01-07 Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr

2000-01-07 Publication of NO20000089D0 publication Critical patent/NO20000089D0/no

2000-02-22 Publication of NO20000089L publication Critical patent/NO20000089L/no

2003-04-14 Publication of NO314581B1 publication Critical patent/NO314581B1/no

Links

150000001412 amines Chemical class 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 34
150000001875 compounds Chemical class 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims abstract description 22
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 21
239000002253 acid Substances 0.000 claims abstract description 15
150000003839 salts Chemical class 0.000 claims abstract description 15
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
LNSCNEJNLACZPA-QZTJIDSGSA-N C1(=C(C=CC=C1)[C@@]([C@@](C(=O)O)(O)C1=C(C=CC=C1)C)(O)C(=O)O)C Chemical compound C1(=C(C=CC=C1)[C@@]([C@@](C(=O)O)(O)C1=C(C=CC=C1)C)(O)C(=O)O)C LNSCNEJNLACZPA-QZTJIDSGSA-N 0.000 claims description 5
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
238000001640 fractional crystallisation Methods 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
239000012670 alkaline solution Substances 0.000 claims description 2
238000004587 chromatography analysis Methods 0.000 claims description 2
DCMJBKFKXGPPMT-UHFFFAOYSA-N n,n-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=NN1C DCMJBKFKXGPPMT-UHFFFAOYSA-N 0.000 claims description 2
-1 neptane Substances 0.000 claims description 2
239000003208 petroleum Substances 0.000 claims description 2
239000011541 reaction mixture Substances 0.000 claims description 2
238000010992 reflux Methods 0.000 claims description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
239000008096 xylene Substances 0.000 claims description 2
DCMJBKFKXGPPMT-HNNXBMFYSA-N n,n-dimethyl-2-[(s)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C1([C@@H](OCCN(C)C)C=2C=CC=CC=2)=CC=NN1C DCMJBKFKXGPPMT-HNNXBMFYSA-N 0.000 claims 1
230000000202 analgesic effect Effects 0.000 abstract description 2
239000010413 mother solution Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
OBCUSTCTKLTMBX-VIFPVBQESA-N (2s)-2-acetyloxy-2-phenylacetic acid Chemical compound CC(=O)O[C@H](C(O)=O)C1=CC=CC=C1 OBCUSTCTKLTMBX-VIFPVBQESA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
SXERGJJQSKIUIC-UHFFFAOYSA-N 2-Phenoxypropionic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1 SXERGJJQSKIUIC-UHFFFAOYSA-N 0.000 description 1
KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
IHINWFFCQSIMFU-UHFFFAOYSA-N OC1(C(CC(C(C1)O)O)O)C(=O)O Chemical compound OC1(C(CC(C(C1)O)O)O)C(=O)O IHINWFFCQSIMFU-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
KMYRYKRXHHWKJI-UHFFFAOYSA-N [N+](=O)([O-])OC(C(O)C(O)C(=O)O)=O Chemical compound [N+](=O)([O-])OC(C(O)C(O)C(=O)O)=O KMYRYKRXHHWKJI-UHFFFAOYSA-N 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229960002303 citric acid monohydrate Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Pharmacology & Pharmacy (AREA)
Pain & Pain Management (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Luminescent Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Gyroscopes (AREA)

NO20000089A 1997-07-10 2000-01-07 Opplösning av aminer NO314581B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES009701538A ES2130079B1 (es)	1997-07-10	1997-07-10	Resolucion de aminas
PCT/ES1998/000195 WO1999002500A1 (es)	1997-07-10	1998-07-06	Resolucion de aminas

Publications (3)

Publication Number	Publication Date
NO20000089D0 NO20000089D0 (no)	2000-01-07
NO20000089L NO20000089L (no)	2000-02-22
NO314581B1 true NO314581B1 (no)	2003-04-14

Family

ID=8300022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000089A NO314581B1 (no)	1997-07-10	2000-01-07	Opplösning av aminer

Country Status (12)

Country	Link
US (1)	US6187930B1 (es)
EP (1)	EP1024137B1 (es)
JP (1)	JP2001509505A (es)
AT (1)	ATE250585T1 (es)
AU (1)	AU8111798A (es)
CA (1)	CA2295800A1 (es)
DE (1)	DE69818495T2 (es)
DK (1)	DK1024137T3 (es)
ES (2)	ES2130079B1 (es)
NO (1)	NO314581B1 (es)
PT (1)	PT1024137E (es)
WO (1)	WO1999002500A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5986135A (en) *	1998-09-25	1999-11-16	American Cyanamid Company	Fungicidal trifluoromethylalkylamino-triazolopyrimidines
US6687187B2 (en) *	2000-08-11	2004-02-03	Phonak Ag	Method for directional location and locating system
US20040142929A1 (en) *	2001-07-06	2004-07-22	Ramon Merce-Vidal	Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US7182210B2 (en)	2003-08-19	2007-02-27	Rock-Tenn Shared Services, Llc	Adjustable shelving system
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
ES2244326B1 (es) *	2004-04-05	2007-02-16	Laboratorios Del Dr. Esteve, S.A.	Combinacion de substancias activas.
EP1584335A3 (en) *	2004-04-05	2006-02-22	Laboratorios Del Dr. Esteve, S.A.	Active substance combination comprising a carbinol composition and an opioid
US20060040924A1 (en) *	2004-06-22	2006-02-23	Laboratorios Dr. Esteve S.A.	Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic
EP1671953A1 (en)	2004-12-17	2006-06-21	Laboratorios Del Dr. Esteve, S.A.	Process for obtaining cizolirtine and its enantiomers
EP1671968A1 (en)	2004-12-17	2006-06-21	Laboratorios Del Dr. Esteve, S.A.	Process for obtaining enantiomers of thienylazolylalcoxyethanamines
EP1674465A1 (en)	2004-12-27	2006-06-28	Laboratorios Del Dr. Esteve, S.A.	Process for obtaining enantiomers of thienylazolylalcoxyethanamines
ATE486841T1 (de) *	2005-05-10	2010-11-15	Teva Pharma	Verfahren zur herstellung von pregabalin und salzen daraus
EP1879854B1 (en) *	2005-05-10	2011-09-07	Teva Pharmaceutical Industries Ltd	Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
US7897589B2 (en) *	2005-07-15	2011-03-01	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1757587A1 (en) *	2005-07-15	2007-02-28	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
KR20080034205A (ko) *	2005-09-19	2008-04-18	테바 파마슈티컬 인더스트리즈 리미티드	(ｓ)-프레가발린의 신규한 합성을 위한 주요 중간체인 키랄3-카르바모일메틸-5-메틸 헥산산
EP1820502A1 (en)	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Active substance combination comprising azolylcarbinol compounds
KR20100107500A (ko) *	2008-06-23	2010-10-05	테바 파마슈티컬 인더스트리즈 리미티드	(ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
EP2151234A1 (en) *	2008-07-28	2010-02-10	Laboratorios Del. Dr. Esteve, S.A.	Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
US20100291151A1 (en) *	2009-04-21	2010-11-18	Auspex Pharmaceuticals, Inc.	1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
JP2011057619A (ja) *	2009-09-10	2011-03-24	Tokai Univ	光学活性アミン化合物の製造方法、並びに、ジアステレオマー塩及びその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2742147B1 (fr) *	1995-12-06	1998-02-27	Esteve Labor Dr	Procede de separation de carbinols
DE19601745C1 (de) *	1996-01-19	1997-10-09	Gruenenthal Gmbh	Verfahren zur Racematspaltung von Tramadol

1997
- 1997-07-10 ES ES009701538A patent/ES2130079B1/es not_active Expired - Fee Related
1998
- 1998-07-06 CA CA002295800A patent/CA2295800A1/en not_active Abandoned
- 1998-07-06 AU AU81117/98A patent/AU8111798A/en not_active Abandoned
- 1998-07-06 ES ES98930811T patent/ES2209158T3/es not_active Expired - Lifetime
- 1998-07-06 WO PCT/ES1998/000195 patent/WO1999002500A1/es active IP Right Grant
- 1998-07-06 DE DE69818495T patent/DE69818495T2/de not_active Expired - Fee Related
- 1998-07-06 EP EP98930811A patent/EP1024137B1/en not_active Expired - Lifetime
- 1998-07-06 DK DK98930811T patent/DK1024137T3/da active
- 1998-07-06 JP JP2000502028A patent/JP2001509505A/ja active Pending
- 1998-07-06 AT AT98930811T patent/ATE250585T1/de not_active IP Right Cessation
- 1998-07-06 US US09/462,326 patent/US6187930B1/en not_active Expired - Fee Related
- 1998-07-06 PT PT98930811T patent/PT1024137E/pt unknown
2000
- 2000-01-07 NO NO20000089A patent/NO314581B1/no unknown

Also Published As

Publication number	Publication date
NO20000089D0 (no)	2000-01-07
AU8111798A (en)	1999-02-08
CA2295800A1 (en)	1999-01-21
ES2130079A1 (es)	1999-06-16
DK1024137T3 (da)	2003-12-22
JP2001509505A (ja)	2001-07-24
PT1024137E (pt)	2004-01-30
EP1024137B1 (en)	2003-09-24
US6187930B1 (en)	2001-02-13
EP1024137A1 (en)	2000-08-02
ES2209158T3 (es)	2004-06-16
NO20000089L (no)	2000-02-22
ES2130079B1 (es)	2000-01-16
DE69818495T2 (de)	2004-07-01
ATE250585T1 (de)	2003-10-15
WO1999002500A1 (es)	1999-01-21
DE69818495D1 (de)	2003-10-30

Publication	Publication Date	Title
NO314581B1 (no)	2003-04-14	Opplösning av aminer
NO309606B1 (no)	2001-02-26	5-fenyl-3-(piperidin-4-yl)-1,3,4-oksadiazol-2(3H)-on- derivater, deres fremstilling, og medikamenter og farmasöytiske preparater
NO333586B1 (no)	2013-07-15	Krystallinsk clopidogrel og fremgangsmate for fremstilling derav
FR2614620A1 (fr)	1988-11-04	Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents anti-bacteriens les contenant
NO320313B1 (no)	2005-11-21	Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter, samt farmasoytisk sammensetning som innbefatter dem
CZ219895A3 (en)	1996-03-13	The use of substituted derivatives of 4-phenyl-6-aminonicotinic acid as medicaments
CZ180898A3 (cs)	1999-05-12	Způsob a meziprodukty pro výrobu 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidinu
CZ279745B6 (cs)	1995-06-14	Stereochemicky čistý derivát 2-hydroxycyklopentylamidu ergolinu, jeho použití, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
NL193541C (nl)	2000-01-04	8 Alfa-acylaminoergolinen, werkwijzen voor de bereiding daarvan en preparaten die ze bevatten.
EP0556119B1 (fr)	1997-05-14	Dérivés de pyrrolidine portant en position 3 un groupe acide gras saturé ou non-saturé, procédé pour leur préparation et compositions pharmaceutiques ayant une activité d'inhibiteurs de thromboxane-A2 les contenant
EP0591027A1 (fr)	1994-04-06	Dérivés de pipéridine, leur préparation et leur application en thérapeutique
SK281812B6 (sk)	2001-08-06	Spôsob výroby monohydrátu ropivacain hydrochloridu
CZ20011353A3 (cs)	2001-09-12	(3-tetrahydropyridin-4-yl)indoly pro léčbu psychotických poruch
WO2002102777A2 (en)	2002-12-27	NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE
NO164899B (no)	1990-08-20	Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolylindolforbindelser.
AU2001278094A1 (en)	2003-05-15	Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride
FR2753970A1 (fr)	1998-04-03	Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
NO167286B (no)	1991-07-15	Fremgangsmaate for fremstilling av terapeutisk aktive benzotiazepin-derivater.
NO328548B1 (no)	2010-03-15	Nye mandelatsalter av substituerte tetracykliske tetrahydrofuranderivater
US5679674A (en)	1997-10-21	Optically active thiomorpholine derivatives
EP2107061A1 (en)	2009-10-07	Process for the preparation of optically enriched clopidogrel
NO173010B (no)	1993-07-05	Analogifremgangsmaate for fremstilling av terapeutisk aktivt sulfonanilid
EP1192152A1 (fr)	2002-04-03	Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique
FR2647785A1 (fr)	1990-12-07	Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant
AU5488596A (en)	1996-11-18	Synthesis of (s)-3-(2-thienylthio) butyric acid and analogs